Tropisetron diminishes demyelination and disease severity in an animal model of multiple sclerosis
| Autor: | Shiva Javadi, S. E. Mehr, Mahmoud Ghazi-Khansari, Gholamreza Hassanzadeh, Atefeh Aminian, Farshid Noorbakhsh, Ahmad Reza Dehpour, Reza Rahimian, Laya Kafami |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Agonist
Encephalomyelitis Autoimmune Experimental Indoles Multiple Sclerosis medicine.drug_class Tropisetron Biguanides HT3R Pharmacology Granisetron 5-HT3 receptor Myelin oligodendrocyte glycoprotein Mice medicine Animals Serotonin 5-HT3 Receptor Antagonists Cell Proliferation biology Dose-Response Relationship Drug Chemistry General Neuroscience Experimental autoimmune encephalomyelitis Antagonist Serotonin 5-HT3 Receptor Agonists medicine.disease Mice Inbred C57BL Disease Models Animal Treatment Outcome Spinal Cord Immunology biology.protein Leukocytes Mononuclear Drug Therapy Combination Receptors Serotonin 5-HT3 Spleen medicine.drug Demyelinating Diseases |
| Zdroj: | Neuroscience. 248 |
| ISSN: | 1873-7544 |
| Popis: | Tropisetron, a selective 5-HT3 receptor (5-HT3R) antagonist, has been widely used to counteract chemotherapy-induced emesis. New investigations described the immunomodulatory properties of tropisetron which may not be 5HT3R mediated. In the present study, we assessed the potential effects of tropisetron on an animal model of multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE). EAE was induced in C57BL/6 mice by myelin oligodendrocyte glycoprotein peptide (MOG35-55) immunization. Animals were treated with tropisetron (5 mg/kg/day); m-chlorophenylbiguanide (mCPBG), a selective 5-HT3R agonist (10 mg/kg/day); tropisetron (5 mg/kg/day) plus mCPBG (10 mg/kg/day), and granisetron (5 mg/kg/day) intraperitoneally on days 3-35 post-immunization. Treatment with tropisetron and granisetron markedly suppressed the clinical symptoms of EAE (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect